Call for Abstract

4th International Conference on Vascular Dementia, will be organized around the theme “Integrating Recent Discoveries and Interpreting Vascular Dementia Research for Better Health”

Vascular Dementia 2016 is comprised of 24 tracks and 148 sessions designed to offer comprehensive sessions that address current issues in Vascular Dementia 2016.

Submit your abstract to any of the mentioned tracks. All related abstracts are accepted.

Register now for the conference by choosing an appropriate package suitable to you.

Lewy bodies are also found in other brain disorders, including Alzheimer's disease and Parkinson's disease dementia.

Many people with Parkinson's eventually develop problems with thinking and reasoning, and many people with DLB experience movement symptoms, such as hunched posture, rigid muscles, a shuffling walk and trouble initiating movement.

  • Track 1-1Cognitive problems
  • Track 1-2Movement disorders
  • Track 1-3Depression and lewy body dementia
  • Track 1-4Lewy body dementia test
  • Track 1-5Disruption of the autonomic nervous system
  • Track 1-6Early stages of lewy body dementia
  • Track 1-7End stage of lew body dementia
  • Track 1-8Advances in lewy body dementia treatment

Admiral Nurses are specialist dementia nurses who give much-needed practical and emotional support to family carers, as well as the person with dementia.

To offer support to families throughout their experience of dementia that is tailored to their individual needs and challenges.

To provide families with the knowledge to understand the condition and its effects, the skills and tools to improve communication, and provide emotional and psychological support to help family carers carry on caring for their family member.

  • Track 2-1Assessment and evaluation of mental health
  • Track 2-2Cognitive behavioral therapy and family therapy in nursing
  • Track 2-3Primary mental health care and nursing
  • Track 2-4Stress and emotional treatment studies and outcomes

Vascular dementia is the second most common type of dementia (after Alzheimer's disease), affecting around 150,000 people in the UK.

The word dementia describes a set of symptoms that can include memory loss and difficulties with thinking, problem-solving or language. In vascular dementia, these symptoms occur when the brain is damaged because of problems with the supply of blood to the brain. 

  • Track 3-1Advances in vascular dementia cognitive impairment treatment
  • Track 3-2Cognitive impairment
  • Track 3-3Senelity
  • Track 3-4Senile dementia
  • Track 3-5Vascular dementia prognosis

Rapidly progressive dementias (RPDs) are neurological conditions that develop subacutely over weeks to months, or rarely acutely over days. In contrast to most dementing conditions that take years to progress to death, RPD can be quickly fatal. It is critical to evaluate the RPD patient without delay, usually in a hospital setting, as they may have a treatable condition. 

  • Track 4-1Advances in sudden dementia research
  • Track 4-2Autoimmune encephalopathies
  • Track 4-3Chronic degenerative dementias
  • Track 4-4Degenerative dementias
  • Track 4-5Delirium and dementia
  • Track 4-6Prion diseases
  • Track 4-7Progressive dementias

Severe Demnetia is the fifth stage of dementia is the most severe. At this point your loved one cannot function at all without help. They have experienced extreme memory loss. Additionally, they have no understanding of orientation in time or geography.

It is almost impossible to go out and engage in everyday activities, even with assistance. Function in the home is completely gone and help is required for attending to personal needs.

  • Track 5-1Advanced therapeutics for severe dementia
  • Track 5-2Advances in severe dementia research
  • Track 5-3Severe dementia causes
  • Track 5-4Severe dementia test
  • Track 5-5Stages in severe dementia
  • Track 5-6Treatment of severe dementia

Semantic dementia, which has also been called "temporal variant FTD," accounts for 20% of FTD cases. Language difficulty, the predominant complaint of people with SD, is due to the disease damaging the left temporal lobe, an area critical for assigning meaning to words. The language deficit is not in producing speech but is a loss of the meaning, or semantics, of words.

Semantic Dementia is one of the three canonical clinical syndromes associated with front temporal lobar degeneration.

  • Track 6-1Causes of semantic dementia
  • Track 6-2Clinical features of semanic dementia
  • Track 6-3Mild semantic dementia
  • Track 6-4Moderate semantic dementia
  • Track 6-5Severe semantic dementia
  • Track 6-6Treatment of semantic dementia

National Plan to Address Alzheimer’s Disease, a national effort to expand research in Alzheimer’s and related dementias prevention and treatment and to move the most promising drugs from discovery into clinical trials.

The Plan aims to prevent and effectively treat Alzheimer’s and related dementias by 2025. Its foundation is the 2011 National Alzheimer’s Project Act (NAPA), which was developed to create and maintain a national strategy to overcome the disease.

  • Track 7-1Aerobic exercise program
  • Track 7-2Digital engagement for people with dementia
  • Track 7-3Future development of therapies
  • Track 7-4Research in induced pluripotent stem cells
  • Track 7-5Researches in amyloid and tau proteins

Mild cognitive impairment (MCI) is a term used to describe a condition involving problems with cognitive function (their mental abilities such as thinking, knowing and remembering).

People with MCI often have difficulties with day-to-day memory, but such problems are not bad enough to be defined as dementia.

  • Track 11-1Advances in mild dementia research
  • Track 11-2Causes of mild dementia
  • Track 11-3Diagnosis of mild dementia
  • Track 11-4Mild cognitive impairment
  • Track 11-5Mild dementia test

The mainstay of management of vascular dementia is the prevention of new strokes. This includes administering antiplatelet drugs and controlling major vascular risk factors.

Neuroprotective drugs such as nimodipine, propentofylline, and posatirelin are currently under study and may be useful for vascular dementia.

  • Track 12-1Omentum in the treatment of vascular dementia
  • Track 12-2Cholinisterase inhibitors
  • Track 12-3Impact of treatment with N-Acetylcysteine
  • Track 12-4Oral redox polymer therapeutics
  • Track 12-5Snoezellen and Multi sensory stimulation
  • Track 12-6Effect of thioctic and enantiomers
  • Track 12-7Role of phospholipids
  • Track 12-8Effects of brain afobazole

Dementia with Lewy bodies (DLB), also known under a variety of other names including Lewy body dementia (LBD), diffuse Lewy body disease, cortical Lewy body disease, and senile dementia of Lewy type, is a type of dementia closely associated with Parkinson's disease.

It is characterized anatomically by the presence of Lewy bodies, clumps of alpha-synuclein and ubiquitin protein in neurons, detectable in post mortem brain histology. Lewy body dementia affects 1.3 million individuals in the United States alone.

  • Track 13-1Advances in lewy body dementia research
  • Track 13-2Causes of lewy body dementia
  • Track 13-3Lewy body disorders
  • Track 13-4Management of lewy body dementia
  • Track 13-5Muscle rigidity
  • Track 13-6Neurotransmitter abnormalities
  • Track 13-7Symptoms of lewy body dementia

Frontotemporal dementia (frontotemporal lobar degeneration) is an umbrella term for a diverse group of uncommon disorders that primarily affect the frontal and temporal lobes of the brain — the areas generally associated with personality, behavior and language.

In frontotemporal dementia, portions of these lobes atrophy or shrink. Signs and symptoms vary, depending upon the portion of the brain affected. Some people with frontotemporal dementia undergo dramatic changes in their personality and become socially inappropriate, impulsive or emotionally indifferent, while others lose the ability to use language.

  • Track 14-1Frotal lobed dementia
  • Track 14-2Frontal lobed dementia stage
  • Track 14-3Frontal lobed dementia life expectancies
  • Track 14-4Frontal dementia test
  • Track 14-5Advances in frontal dementia research
  • Track 14-6Frontal dementia treatment

Frontotemporal dementia (frontotemporal lobar degeneration) is an umbrella term for a diverse group of uncommon disorders that primarily affect the frontal and temporal lobes of the brain, the areas generally associated with personality, behavior and language.

In frontotemporal dementia, portions of these lobes atrophy or shrink. Signs and symptoms vary, depending upon the portion of the brain affected. 

  • Track 15-1Behavior variant frontotemporal dementia
  • Track 15-2Causes and risks of frontotemporal dementia
  • Track 15-3Diagnosis of frontotemporal dementia
  • Track 15-4Primary progressive aphasia
  • Track 15-5Treatment of frontotemporal dementia

Diagnosing dementia is often difficult, particularly in the early stages. The GP is the first person to consult. The GP may then refer the person being diagnosed to a specialist such as a consultant.

Assessments can include conversations with the person being diagnosed and those close to them, a physical examination, memory tests and/or brain scans.

The Mini Mental State Examination (MMSE) is the most commonly used test for complaints of memory problems or when a diagnosis of dementia is being considered.

  • Track 16-1 Mini Mental State Examination
  • Track 16-2Blood tests for dementia
  • Track 16-3Brain imaging techniques
  • Track 16-4Cognitive testing
  • Track 16-5Dementia brain scans
  • Track 16-6Neuropsychological testing
  • Track 16-7Radiological tests

Progressive dementia, which is dementia that gets worse with time, is the most common type. Five stages of progressive dementia have been outlined. They are part of the Clinical Dementia Rating (CDR), which professionals use to evaluate the progression of symptoms in patients with dementia.

The five stages describe a patient’s ability to perform in six different areas of cognition and functioning: orientation, memory, judgment, home and hobbies, personal care, and community.

  • Track 17-1Advanced dementia
  • Track 17-2Advances in research of dementia stages
  • Track 17-3Early dementia
  • Track 17-4Moderate dementia
  • Track 17-5Test of dementia stages

Vascular disease is mainly caused by hardening of the arteries (atherosclerosis) due to a thickening of the artery lining from fatty deposits or plaques (atheroma).

Vascular disease may manifest acutely when thrombi, emboli, or acute trauma compromises perfusion. Thrombosis are often of an athermanous nature and occur in the lower extremities more frequently than in the upper extremities. Multiple factors predispose patients for thrombosis. These factors include sepsis, hypotension, low cardiac output, aneurysms, aortic dissection, bypass grafts, and underlying atherosclerotic narrowing of the arterial lumen.

  • Track 18-1Peripheral artery disease
  • Track 18-2Aneurysm
  • Track 18-3Amyloid cascade and tau pathology
  • Track 18-4Vascular pathology in aging brain
  • Track 18-5Protein trafficking and synaptic pathology
  • Track 18-6White matter pathology in vascular cogitive disease
  • Track 18-7Hippocampal pathology in aged
  • Track 18-8Retinal pathology in susac syndrome
  • Track 18-9Cerebral amyloid angiopathy

Dementia is a group of symptoms that can occur as a result of some diseases that damage the brain (examples of such diseases: Alzheimer’s Disease, strokes, Fronto-Temporal Dementia, Lewy Body Dementia, etc).

The abilities of persons with dementia decline in many ways. This affects them and everyone around them–family members, friends, colleagues, etc.

  • Track 19-1Pediatric dementia
  • Track 19-2Nutritional factors and dementia
  • Track 19-3Malnutrition, undernutrition and obesity in dementia
  • Track 19-4Palliative care in vascular dementia
  • Track 19-5Natural remedies for the treatment
  • Track 19-6Advanced researches for dementia care
  • Track 19-7Advances in neuropharmacology in brain protection and recovery
  • Track 19-8Role of dietry nitrates
  • Track 19-9Music Therapy in Dementia
  • Track 19-10Advance Care Planning
  • Track 19-11End of life care and grief in dementia
  • Track 19-12Admiral Nursing
  • Track 19-13Antipsychotic medications
  • Track 19-14Betrothal therapy

Dementia is the loss of cognitive functioning, which means the loss of the ability to think, remember, or reason, as well as behavioural abilities, to such an extent that it interferes with a person’s daily life and activities.

Vascular dementia and vascular cognitive impairment (VCI) are caused by injuries to the vessels supplying blood to the brain. These disorders can be caused by brain damage from multiple strokes or any injury to the small vessels carrying blood to the brain.

  • Track 20-1Stroke-related dementia
  • Track 20-2Post stroke dementia
  • Track 20-3Subcortical vascular dementia
  • Track 20-4Mixed dementia
  • Track 20-5Multi-infarct dementia
  • Track 20-6Young onset dementia
  • Track 20-7Sleep and dementia
  • Track 20-8White matter and dementia
  • Track 20-9Computational/ Mathematical modelling of dementia
  • Track 20-10Parkinson dementia

Alcohol-related dementia is a broad term currently preferred among medical professionals.

Many experts use the terms alcohol (or alcoholic) dementia to describe a specific form of ARD, characterized by impaired executive function (planning, thinking, and judgment).

Another form of ARD is known as wet brain (Wernicke-Korsakoff syndrome), characterized by short term memory loss and thiamine (vitamin B1) deficiency. ARD patients often have symptoms of both forms, i.e. impaired ability to plan, apathy, and memory loss. ARD may occur with other forms of dementia (mixed dementia). The diagnosis of ARD is widely recognized but rarely applied, due to a lack of specific diagnostic criteria.

  • Track 21-1Advances in the prevention of alcoholic dementia
  • Track 21-2Alcoholic dementia test
  • Track 21-3Causes of alcoholic dementia
  • Track 21-4Treatment for alcoholic dementia
  • Track 21-5Wernicke-Korsakoff Syndrome

Almost 40 per cent of people over the age of 65 experience some form of memory loss. When there is no underlying medical condition causing this memory loss, it is known as "age-associated memory impairment," which is considered a part of the normal aging process.

Brain diseases like Alzheimer’s disease and other dementias are different.

Age-associated memory impairment and dementia can be told apart in a number of ways.

  • Track 22-1Advances of research in ageing and dementia
  • Track 22-2Brain ageing and dementia
  • Track 22-3Functional imaging test
  • Track 22-4Neuro-anatomical changes in ageing
  • Track 22-5Normal ageing and dementia
  • Track 22-6Risk factors of cognitive decline

A range of tests and diagnostic procedures is needed to diagnose dementia, but there are several that are fairly commonly used to diagnose dementia.

These tests for dementia are mainly tests of mental abilities, blood tests and brain scans.

Tests can help the doctor learn whether dementia is caused by a treatable condition. Even for those dementias that cannot be reversed, knowing the type of dementia a person has can help the doctor prescribe medicines or other treatments that may improve mood and behavior and help the family.

  • Track 23-1Diagnosis of vascular dementia
  • Track 23-2Vascular dementia test
  • Track 23-3Neuroimaging
  • Track 23-4Biomarkers
  • Track 23-5Amyloid and tau imaging
  • Track 23-6Diffusion kurtosis imaging
  • Track 23-7Radiology
  • Track 23-8Hippocampal diffusion tensor imaging
  • Track 23-9Positron emission tomography
  • Track 23-10EEG and brain mapping
  • Track 23-11MR spectroscopy
  • Track 23-12Advances in the field of imaging
  • Track 23-13Role of neurosonsology

Brain is an intangible conundrum which buries millions and millions of memories.

Entrepreneurship is the process of designing a new business, i.e. a startup company offering a product, process or service.

We are convinced that these new approaches to entrepreneurship research will have high impact and will lead to some of the most exciting and best publications in the years to come.

Bringing these new approaches together in one track will provide a forum for some of the best scholars in the field to join Vascular Dementia Conference 2016 and it will provide the audience with a look into the future of entrepreneurship research.

 

  • Track 24-1Simulation semantics
  • Track 24-2Cognitive science
  • Track 24-3Computational theory of mind
  • Track 24-4Next generation of entrepreneurs in neuroscience
  • Track 24-5Neuroscience and brain game
  • Track 24-6Neuromanagement
  • Track 24-7Neuro-industrial-engineering